Sagaliam Seeks Additional Year to Seal Deal with Enzolytics Subsidiaries

SAgaliam Acquisition in a proxy filing proposes a 12-month extension Nov. 23, 2024 to complete a merger.

Sagaliam last month executed a binding business combination agreement for the purchase of Biogenysis, and Virogentics, operating subsidiaries of Enzolytics.

The SPAC in June amended a non-binding term sheet for the purchase of Enzolytics to $450 million. The initial term sheet called for a purchase price of $250 million.

Sagaliam expects to raise additional capital through a PIPE to fund the deal.

Enzolytics is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases.

Sagaliam in March terminated a merger agreement with Arabian Entertainment.

The SPAC raised about $116 million in a December 2021 IPO, but lost almost 92% to redemptions in December 2022. The SPAC as of June held nearly $10 million in trust. Read more.

Total
0
Shares
Related Posts